👨⚕️ "The Truth about Testosterone Therapy & Prostate Cancer Risk!"
Imaging for High-Risk Prostate Cancer: The Guidelines and Beyond
I Had A 212 PSA When I was Diagnosed With Prostate Cancer
Prostate Cancer Breakthrough Urine Test Avoids Unnecessary Biopsies
10 Must-Eat Foods To shrink Enlarged Prostate & 10 to Avoid"
Prostate Cancer Webinar: Research & Prostate Cancer-Related Fatigue
COMMENTS
Advances in Prostate Cancer Research
Learn about the latest research and clinical advances in prostate cancer, including early detection, diagnosis, and new treatments. Find out how NCI-funded programs and studies are fueling progress and improving outcomes.
FDA Approves Promising Therapy for Advanced Prostate Cancer ...
Prostatecanceris the second leading cause of cancer death in American males and kills 34,000 people in the U.S. every year. The FDA approval is the latest bold advance in the emerging field of theranostics, which uses radioactive substances to visualize cancer cells and destroy them without harming normal cells.
The Lancet Commission on prostate cancer: planning for the ...
Prostatecancer is the most common cancer in men in112 countries, and accounts for 15% of cancers. In this Commission, we report projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy.
Prostate cancer - Latest research and news | Nature
Latest Research and Reviews. Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostatecancer patients progressing while on androgen deprivation therapy. John Nikitas. Andrei...
FDA approves new treatment for advanced prostate cancer
In June, the FDA approved a new treatment for the most advanced type of prostate cancer. Patients who have this condition, which is calledmetastaticcastration-resistant prostate cancer (mCRPC), have few therapeutic options, so the approval helps to fill an urgent need.
A Promising New Therapy for Advanced Prostate Cancer
Prostate cancer treatment stands on the brink of a major advance with the development of a new treatment that zeros in on cancer cells to destroy them. The therapy, called177Lu-PSMA-617, uses a molecule that selectively seeks out and attaches to a specific protein on the cancer cell surface.
IMAGES
VIDEO
COMMENTS
Learn about the latest research and clinical advances in prostate cancer, including early detection, diagnosis, and new treatments. Find out how NCI-funded programs and studies are fueling progress and improving outcomes.
Prostate cancer is the second leading cause of cancer death in American males and kills 34,000 people in the U.S. every year. The FDA approval is the latest bold advance in the emerging field of theranostics, which uses radioactive substances to visualize cancer cells and destroy them without harming normal cells.
Prostate cancer is the most common cancer in men in 112 countries, and accounts for 15% of cancers. In this Commission, we report projections of prostate cancer cases in 2040 on the basis of data for demographic changes worldwide and rising life expectancy.
Latest Research and Reviews. Phase 2 trial of PSMA PET CT versus planar bone scan and CT in prostate cancer patients progressing while on androgen deprivation therapy. John Nikitas. Andrei...
In June, the FDA approved a new treatment for the most advanced type of prostate cancer. Patients who have this condition, which is called metastatic castration-resistant prostate cancer (mCRPC), have few therapeutic options, so the approval helps to fill an urgent need.
Prostate cancer treatment stands on the brink of a major advance with the development of a new treatment that zeros in on cancer cells to destroy them. The therapy, called 177 Lu-PSMA-617, uses a molecule that selectively seeks out and attaches to a specific protein on the cancer cell surface.